Aligos announces data from two presentations at CROI on pevifoscorvir sodium

Aligos Therapeutics (ALGS) announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections, CROI, being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. “We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection,” said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. “Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year.”